Abciximab
Phase 1/2Withdrawn 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Abciximab
Abciximab is a phase 1/2 stage product being developed by Eli Lilly for Carotid Stenosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00178451. Target conditions include Carotid Stenosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00178451 | Phase 1/2 | Withdrawn |
| NCT00440895 | Approved | Completed |
| NCT00440778 | Approved | Completed |
| NCT00420030 | Approved | Completed |
| NCT00354406 | Approved | Completed |
| NCT00167765 | Phase 3 | Terminated |
| NCT00126139 | Phase 3 | Terminated |
| NCT00073372 | Phase 3 | Terminated |
| NCT00169819 | Approved | Completed |
Competing Products
9 competing products in Carotid Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg | AstraZeneca | Approved | 85 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| simvastatin + placebo | Merck | Pre-clinical | 23 |
| Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin | Merck | Phase 2 | 52 |
| Evolocumab | Amgen | Approved | 84 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Rimonabant + Placebo (for Rimonabant) | Sanofi | Phase 3 | 76 |
| Gadobutrol (Gadovist, BAY86-4875) | Bayer | Phase 3 | 74 |